ReviewZeitschrift fur Rheumatologie2016
[Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance].
Review in Zeitschrift fur Rheumatologie, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.Frontiers in immunology · 2023Review
- Article
- Deep Neck Infection in Systemic Lupus Erythematosus Patients: Real-World Evidence.Scientific reports · 2020Article
- [Research advances in immune tolerance of allogeneic cell transplantation in preterm infants].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018Review
- [IL-2-Therapy in SLE- Selective reconstitution of immunological tolerance].Zeitschrift fur Rheumatologie · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) results from loss of immunological tolerance. Regulatory T‑cells (Treg) are major gatekeepers of peripheral tolerance by suppression of autoreactive lymphocytes. Defects in Treg function are therefore possible pathogenetic mechanisms of SLE. Despite this fact published work about numbers and functions of Tregs in SLE are contradictory and the definitive role of Treg in SLE remains unclear. In this review we summarize the current literature about Treg subtypes and the phenotypic markers in human SLE. We also discuss data from mouse models and ex vivo experiments, which provide indications for possible mechanisms that contribute to loss of tolerance. We also discuss the role of interleukin 2 (IL-2), which is decisive for the function of Treg and has been used therapeutically in preliminary trials in human SLE. The identification of novel Treg markers and the development of novel therapeutic approaches, which restore the balance between Treg and autoreactive T‑cells are future goals for research in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.